Last reviewed · How we verify

NCT05302375: iPath Pilot

Developing and Testing an Online Pathway From Screening to Treatment for Depression in Oncology: iPath*D (Aim 2)

Recruiting now NA Last updated 3 April 2025
What this trial tests

NA trial testing iPath*D in Cancer in 30 participants. Currently enrolling.

Timeline
1 July 2024
Primary endpoint
30 June 2025
15 December 2025

Quick facts

Lead sponsorDartmouth-Hitchcock Medical Center
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposeother
Enrollment30
Start date1 July 2024
Primary completion30 June 2025
Estimated completion15 December 2025
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Dartmouth-Hitchcock Medical Center

Who can join

18 and older, any sex, with Cancer or Depression. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to determine the extent to which an online pathway to depression treatment (iPath\*D) is acceptable and usable to patients receiving cancer treatment who report symptoms of depression.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Cancer

Currently open trials in the same condition.

Other Dartmouth-Hitchcock Medical Center trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05302375.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing